S&P 500   5,010.67 (+0.87%)
DOW   38,250.43 (+0.70%)
QQQ   418.57 (+0.95%)
AAPL   166.25 (+0.76%)
MSFT   400.13 (+0.25%)
META   482.70 (+0.34%)
GOOGL   156.35 (+1.47%)
AMZN   176.89 (+1.29%)
TSLA   141.91 (-3.50%)
NVDA   790.43 (+3.73%)
AMD   148.10 (+1.00%)
NIO   4.01 (+5.53%)
BABA   70.83 (+2.55%)
T   16.29 (-1.33%)
F   12.83 (+5.68%)
MU   109.07 (+2.15%)
GE   150.23 (+1.47%)
CGC   7.81 (-1.51%)
DIS   112.34 (-0.24%)
AMC   3.41 (+7.91%)
PFE   26.35 (+1.35%)
PYPL   63.37 (+1.70%)
XOM   120.66 (+0.65%)
S&P 500   5,010.67 (+0.87%)
DOW   38,250.43 (+0.70%)
QQQ   418.57 (+0.95%)
AAPL   166.25 (+0.76%)
MSFT   400.13 (+0.25%)
META   482.70 (+0.34%)
GOOGL   156.35 (+1.47%)
AMZN   176.89 (+1.29%)
TSLA   141.91 (-3.50%)
NVDA   790.43 (+3.73%)
AMD   148.10 (+1.00%)
NIO   4.01 (+5.53%)
BABA   70.83 (+2.55%)
T   16.29 (-1.33%)
F   12.83 (+5.68%)
MU   109.07 (+2.15%)
GE   150.23 (+1.47%)
CGC   7.81 (-1.51%)
DIS   112.34 (-0.24%)
AMC   3.41 (+7.91%)
PFE   26.35 (+1.35%)
PYPL   63.37 (+1.70%)
XOM   120.66 (+0.65%)
S&P 500   5,010.67 (+0.87%)
DOW   38,250.43 (+0.70%)
QQQ   418.57 (+0.95%)
AAPL   166.25 (+0.76%)
MSFT   400.13 (+0.25%)
META   482.70 (+0.34%)
GOOGL   156.35 (+1.47%)
AMZN   176.89 (+1.29%)
TSLA   141.91 (-3.50%)
NVDA   790.43 (+3.73%)
AMD   148.10 (+1.00%)
NIO   4.01 (+5.53%)
BABA   70.83 (+2.55%)
T   16.29 (-1.33%)
F   12.83 (+5.68%)
MU   109.07 (+2.15%)
GE   150.23 (+1.47%)
CGC   7.81 (-1.51%)
DIS   112.34 (-0.24%)
AMC   3.41 (+7.91%)
PFE   26.35 (+1.35%)
PYPL   63.37 (+1.70%)
XOM   120.66 (+0.65%)
S&P 500   5,010.67 (+0.87%)
DOW   38,250.43 (+0.70%)
QQQ   418.57 (+0.95%)
AAPL   166.25 (+0.76%)
MSFT   400.13 (+0.25%)
META   482.70 (+0.34%)
GOOGL   156.35 (+1.47%)
AMZN   176.89 (+1.29%)
TSLA   141.91 (-3.50%)
NVDA   790.43 (+3.73%)
AMD   148.10 (+1.00%)
NIO   4.01 (+5.53%)
BABA   70.83 (+2.55%)
T   16.29 (-1.33%)
F   12.83 (+5.68%)
MU   109.07 (+2.15%)
GE   150.23 (+1.47%)
CGC   7.81 (-1.51%)
DIS   112.34 (-0.24%)
AMC   3.41 (+7.91%)
PFE   26.35 (+1.35%)
PYPL   63.37 (+1.70%)
XOM   120.66 (+0.65%)

BioLineRx (BLRX) Earnings Date, Estimates & Call Transcripts

$0.66
+0.00 (+0.03%)
(As of 03:35 PM ET)

Earnings Summary

Upcoming
Earnings Date
May. 22Estimated
Actual EPS
(Mar. 28)
-$0.15 Beat By $0.07
Consensus EPS
(Mar. 28)
-$0.22
Skip Charts & View Estimated and Actual Earnings Data

BLRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BLRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

BioLineRx Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242($0.29)($0.15)($0.22)
Q2 20242($0.29)($0.14)($0.22)
Q3 20242($0.24)($0.15)($0.20)
Q4 20242($0.22)($0.09)($0.16)
FY 20248($1.04)($0.53)($0.79)

BLRX Earnings Date and Information

BioLineRx last released its quarterly earnings data on March 28th, 2024. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.07. The firm had revenue of $4.80 million for the quarter, compared to analyst estimates of $0.17 million. BioLineRx has generated ($0.90) earnings per share over the last year (($0.90) diluted earnings per share). Earnings for BioLineRx are expected to grow in the coming year, from ($1.03) to ($0.93) per share. BioLineRx has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 22nd, 2024 based off prior year's report dates.

BioLineRx Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/22/2024
Estimated)
------- 
3/28/2024Q4 2023($0.22)($0.15)+$0.07($0.15)$0.17 million$4.80 million    
11/20/2023Q3 2023($0.18)($0.30)($0.12)($0.30)--  
8/30/2023Q2 2023($0.16)($0.30)($0.14)($0.30)--  
5/24/2023Q1 2023($0.14)($0.15)($0.01)($0.15)--
3/22/2023Q4 2022($0.14)($0.09)+$0.05($0.09)--
11/15/2022Q3 2022($0.16)($0.15)+$0.01($0.15)--
8/16/2022Q2 2022($0.14)($0.16)($0.02)($0.16)--
5/11/2022Q1 2022($0.15)($0.10)+$0.05($0.10)--
3/16/2022Q4 2021($0.14)($0.08)+$0.06($0.08)--
12/8/2021Q3($0.16)($0.15)+$0.01---  
11/18/2021Q3 2021($0.13)($0.23)($0.10)($0.23)--
8/18/2021Q2($0.12)($0.15)($0.03)($0.15)--    
5/26/2021Q1 2021($0.15)($0.27)($0.12)($0.27)--

BioLineRx Earnings - Frequently Asked Questions

When is BioLineRx's earnings date?

BioLineRx has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 22nd, 2024 based off last year's report dates. Learn more on BLRX's earnings history.

Did BioLineRx beat their earnings estimates last quarter?

In the previous quarter, BioLineRx (NASDAQ:BLRX) reported ($0.15) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.22) by $0.07. Learn more on analysts' earnings estimate vs. BLRX's actual earnings.

How can I listen to BioLineRx's earnings conference call?

The conference call for BioLineRx's latest earnings report can be listened to online. Listen to Conference Call

How can I read BioLineRx's conference call transcript?

The conference call transcript for BioLineRx's latest earnings report can be read online. Read Transcript

How much revenue does BioLineRx generate each year?

BioLineRx (NASDAQ:BLRX) has a recorded annual revenue of $4.80 million.

How much profit does BioLineRx generate each year?

BioLineRx (NASDAQ:BLRX) has a recorded net income of -$60.61 million. BLRX has generated -$0.90 earnings per share over the last four quarters.

What is BioLineRx's EPS forecast for next year?

BioLineRx's earnings are expected to grow from ($1.03) per share to ($0.93) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:BLRX) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners